Steinke John W, Borish Larry
Asthma and Allergic Disease Center, Beirne Carter Center for Immunology Research, University of Virginia Health System, Charlottesville, 22908-1355, USA.
Curr Allergy Asthma Rep. 2004 May;4(3):217-23. doi: 10.1007/s11882-004-0029-x.
Cysteinyl leukotrienes (CysLTs) mediate their biologic activities through interactions with the CysLT1 and CysLT2 receptors. CysLT1 receptors are prominently expressed on smooth muscle cells and lung fibroblasts, whereas CysLT2 receptors are expressed on heart Purkinje fiber cells, adrenal chromaffin cells, and endothelial cells. Both receptors are expressed on eosinophils and mast cells, but CysLT1 receptors alone are on neutrophils. Antigen-presenting cells more prominently express the type 2 receptor. CysLT1 receptors are uniquely important for bronchospasm, whereas CysLT2 receptors can stimulate endothelial cell adherence, myofibroblast proliferation, and chemokine production by mast cells. Comprehensive inhibition of the proinflammatory activities of CysLTs might require either combination CysLT1 and CysLT2 receptor antagonists or inhibitors of the CysLT synthesis pathway.
半胱氨酰白三烯(CysLTs)通过与CysLT1和CysLT2受体相互作用介导其生物学活性。CysLT1受体在平滑肌细胞和肺成纤维细胞上显著表达,而CysLT2受体在心脏浦肯野纤维细胞、肾上腺嗜铬细胞和内皮细胞上表达。两种受体均在嗜酸性粒细胞和肥大细胞上表达,但仅CysLT1受体在中性粒细胞上表达。抗原呈递细胞更显著地表达2型受体。CysLT1受体对支气管痉挛尤为重要,而CysLT2受体可刺激内皮细胞黏附、肌成纤维细胞增殖以及肥大细胞产生趋化因子。全面抑制CysLTs的促炎活性可能需要联合使用CysLT1和CysLT2受体拮抗剂或CysLT合成途径抑制剂。